<div id="readability-page-1"><p>Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,960,000 shares,  a decline of 22.1% from the April 30th total of 3,800,000 shares. Approximately 6.2% of the company's stock are short sold. Based on an average daily volume of 2,690,000 shares, the short-interest ratio is currently 1.1 days.</p><h2>Insider Transactions at Checkpoint Therapeutics</h2><p>In other news, CEO James F. Oliviero III sold 15,090 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total transaction of $60,963.60. Following the transaction, the chief executive officer now directly owns 3,759,929 shares of the company's stock, valued at approximately $15,190,113.16. This trade represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CFO William Garrett Gray sold 12,322 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total transaction of $49,904.10. Following the sale, the chief financial officer now owns 1,446,322 shares in the company, valued at $5,857,604.10. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own  2.10% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. purchased a new stake in shares of  Checkpoint Therapeutics during the fourth quarter worth $32,000.  Tower Research Capital LLC TRC increased its position in  Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock worth $34,000 after purchasing an additional 6,486 shares during the last quarter.  Virtu Financial LLC raised its stake in shares of  Checkpoint Therapeutics by 180.5% during the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company's stock worth $122,000 after purchasing an additional 24,552 shares in the last quarter.  Stifel Financial Corp purchased a new stake in shares of  Checkpoint Therapeutics during the 4th quarter worth about $32,000.  Finally, Raymond James Financial Inc. acquired a new stake in shares of  Checkpoint Therapeutics during the 4th quarter valued at about $67,000. Institutional investors and hedge funds own  22.00% of the company's stock. </p><h2>Checkpoint Therapeutics Price Performance</h2><p>Shares of NASDAQ:CKPT opened at $4.26 on Monday. The company's fifty day moving average is $4.09 and its two-hundred day moving average is $3.68. The company has a market cap of $370.71 million, a P/E ratio of -2.32 and a beta of 1.18. Checkpoint Therapeutics has a 12-month low of $1.80 and a 12-month high of $4.50. </p><p>Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.09).  Equities research analysts anticipate that  Checkpoint Therapeutics will post -0.94 earnings per share for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities research analysts have recently weighed in on the company. D. Boral Capital  reissued a &#34;buy&#34; rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a research note on Monday, March 31st. Lake Street Capital  reiterated a &#34;hold&#34; rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, HC Wainwright  restated a &#34;neutral&#34; rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.</p><p><b>Read Our Latest Analysis on Checkpoint Therapeutics</b></p><h2>About Checkpoint Therapeutics</h2> (Get Free Report)<p>Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.</p><h2>Read More</h2><ul><li>Five stocks we like better than Checkpoint Therapeutics</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>Why Dollar General May Be Retail’s Most Undervalued Rebound</li><li>NYSE Stocks Give Investors a Variety of Quality Options </li><li>3 Smart Ways to Play the Crypto Boom—No Coins Needed</li><li>What is Forex and How Does it Work? </li><li>3 Top-Rated Energy Companies Staging Strong Recoveries</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Checkpoint Therapeutics Right Now?</h2><p>Before you consider Checkpoint Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.</p><p>While Checkpoint Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CKPT

<p>Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) experienced a 22.1% drop in short interest in May, totaling 2,960,000 shares. Currently, 6.2% of its shares are sold short, with a days-to-cover ratio of 1.1 days. CEO James F. Oliviero III and CFO William Garrett Gray sold shares recently, reducing their ownership. Institutional investors hold 22% of the stock. The company's stock opened at $4.26, with a market cap of $370.71 million. Analysts have mixed ratings, with price targets ranging from $4.10 to $4.80.</p>

Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Drops By 22.1%